Full information on isolate 19121 (id:17192)
- strain designation
- W: P1.5,2: F1-1: ST-11 (cc11)
- invasive (unspecified/other)
- Neisseria meningitidis
- genogroup notes
- W backbone: All essential capsule genes intact and present. Prediction code: https://github.com/ntopaz/characterize_neisseria_capsule.
- capsule group
- sero subtype
- penicillin range
- >0.06 - 1 (intermediate)
- Muhamed-Kheir Taha, National Reference Center for Meningococci and Haemophilus influenzae, Institut Pasteur, France
- Auto Tagger
- update history
- 49 updates show details
- date entered
Bexsero® (4CMenB) is a multicomponent vaccine.
- Protein-based meningococcal vaccines contain surface proteins as vaccine antigens, these proteins demonstrate nucleotide and amino acid sequence diversity.
- Peptide sequence diversity can be analysed using the Bexsero Antigen Sequence Typing (BAST) scheme1.
- Bexsero® contains: fHbp peptide 1; NHBA peptide 2; NadA peptide 8; PorA VR2 4.
The Deduced Vaccine Antigen Reactivity (MenDeVAR) Index was developed to combine multiple, complex data that inform the reactivity of each vaccine against specific antigenic variants.
The MenDeVAR Index:
- isolate contains ≥1 exact sequence match to antigenic variants found in the vaccine.
- isolate contains ≥1 antigenic variant deemed cross-reactive to vaccine variants through experimental studies.
- all the isolate's antigenic variants have been deemed not cross-reactive to vaccine variants through experimental studies.
- isolate contains antigens for which there is insufficient data from or are yet to be tested in experimental studies.
It is important to understand the caveats to interpreting the MenDeVAR Index:
Source of data - These data combine multiple sources of information including: peptide sequence identity through whole genome sequencing; experimental assays developed as indirect measures of the breadth of vaccine protection against diverse meningococci; and assays developed to assess immunogenicity. The Meningococcal Antigen Typing System (MATS)2 assay was used for Bexsero®.
Cross-reactivity definition - An antigenic variant was considered cross-reactive if it had been tested in ≥5 isolates/subjects and was above the accepted threshold in ≥75% of those isolates. This was established through combined analysis of published experimental studies (PMID provided for each variant), not from genomic data. These assays were based on serogroup B disease isolates.
Protein expression - We have not inferred from genomic data, therefore there may be isolates that possess genes but do no express the protein in vivo.
Age of vaccinees - For MATS assay development2, Bexsero® vaccine recipients were infants who had received 3 doses of vaccine and then a booster at 12 months. The pooled sera used for the MATS assay were taken from the toddlers at 13 months of age.
- Brehony C, Rodrigues CMC, Borrow R, et al. Distribution of Bexsero® Antigen Sequence Types (BASTs) in invasive meningococcal disease isolates: Implications for immunisation. Vaccine 2016 34(39):4690-7
- Donnelly J, Medini D, Boccadifuoco G, et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci USA 2010;107(45):19490-19495
Click to close
- total length
- 2,063,391 bp
- max length
- 97,233 bp
- mean length
- 17,487 bp
- N50 contig number
- N50 length (L50)
- N90 contig number
- N90 length (L90)
- N95 contig number
- N95 length (L95)
- loci tagged
Similar isolates (determined by classification schemes)
Experimental schemes are subject to change and are not a stable part of the nomenclature.
|Classification scheme||Underlying scheme||Clustering method||Mismatch threshold||Status||Group|
|Nm_cgc_200||N. meningitidis cgMLST v1.0||Single-linkage||200||experimental||group: 65 (3469 isolates)|
|Nm_cgc_100||N. meningitidis cgMLST v1.0||Single-linkage||100||experimental||group: 87 (910 isolates)|
|Nm_cgc_50||N. meningitidis cgMLST v1.0||Single-linkage||50||experimental||group: 104 (892 isolates)|
Schemes and loci
- All loci
- Genetic Information Processing
- Aminotransferase (transaminase)
- DNA Replication
- Transcription factors
- Transcription machinery
- transfer RNA Biogenesis
- 3' processing and CCA adding factors
- 5' processing factors
- Aminoacyl-tRNA synthetases (AARSs)
- tRNA modification factors
- transfer RNA Biogenesis
- Genomic islands
- Lineage Schemes
- Carbohydrate Metabolism
- Glycan Biosynthesis and Metabolism
- Nucleotide Metabolism
- Other schemes
- Loci not in schemes